Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
about
Invasive mold infections in solid organ transplant recipientsMucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia speciesStability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphoterComparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosisHow I treat mucormycosis.Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Our 2014 approach to mucormycosis.Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis.Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.Successful Treatment of Pulmonary Mucormycosis Caused by Cunninghamella bertholletiae with High-Dose Liposomal Amphotericin B (10 mg/kg/day) Followed by a Lobectomy in Cord Blood Transplant Recipients.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
P2860
Q26823811-EAD7B616-280A-4D55-8C52-93107E99A49FQ28389719-8807834E-18F1-4E5A-9718-C9AEC7513562Q34315804-55AF713E-1095-41A6-BBE8-9D8273BF96C4Q34596761-2EF84B2C-1254-4351-99D1-B4FCEAEF4C6BQ35065748-6927F225-B331-4EB6-A041-2EA7E6700268Q35797637-BCD1F82B-0984-4CA3-AE04-D5D659E253C6Q36862446-EA95DC1B-0C36-432C-8928-6367B9F9624BQ36868273-E5571566-C5FE-4EE6-A125-27FDEB77FEF0Q38211830-D347EA25-4EA5-4640-83FF-D0EA49D755A2Q38404951-06F239CD-7F6A-4ED0-8FCD-39072B036C2FQ40116878-1053CE29-C58A-4B6C-B71F-FF84D060C573Q40186737-5796DE81-058A-4C2A-B2FA-338636F184F9Q40222438-77E13F74-6B36-4029-AB9C-92CC71821829Q42277564-0F8A359C-183C-444A-8BC9-D5CC2CEB1FBC
P2860
Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@en
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@nl
type
label
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@en
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@nl
prefLabel
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@en
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@nl
P2093
P2860
P356
P1476
Comparative pharmacodynamics o ...... del of pulmonary mucormycosis.
@en
P2093
Dimitrios P Kontoyiannis
Guangling Liao
Jingguo Hou
Nathan D Albert
Randall A Prince
P2860
P304
P356
10.1128/AAC.01222-09
P407
P577
2009-12-28T00:00:00Z